Results 31 to 40 of about 115,882 (349)

Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update

Journal of Clinical Medicine, 2021
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder which is characterized by presence of antibodies against acetylcholine receptors (AChRs) or other proteins of the postsynaptic membrane resulting in damage to postsynaptic membrane, decreased
S. Sheikh, Usman Alvi, B. Soliven, K. Rezania   +3 more
semanticscholar   +1 more source

Is chest tube drainage necessary after subxiphoid thoracoscopic thymectomy?

Journal of Cardiothoracic Surgery, 2020
Background Subxiphoid thoracoscopic thymectomy has been increasingly performed in recent years. This study aimed to assess the differences in outcomes between subxiphoid thoracoscopic thymectomy with and without chest tube drainage.
Jiaduo Li, Guoyan Qi, Xiaohe Zhang, Xuguang Zheng   +3 more
doaj   +1 more source

Anxiety and depression in thymoma patients in China before surgery

Journal of Cardiothoracic Surgery, 2022
Background The study's goal was to investigate the percentage of anxiety and depression in Chinese thymoma patients before surgery, and also the factors that influence it.
Jiaduo Li, Guoyan Qi, Yaling Liu
doaj   +1 more source

Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort

Frontiers in Pediatrics, 2022
Myasthenia gravis is an organ-specific autoimmune disease. Currently there is no universal guidelines for childhood-onset myasthenia gravis, therefore, treatment strategies are usually based on the guidelines from adult myasthenia gravis patients.
Lifen Yang, Yulin Tang, Fang He, Ciliu Zhang, Miriam Kessi, Jing Peng, Fei Yin   +6 more
doaj   +1 more source

Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival

European Journal of Neurology, 2021
Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID‐19) mainly due to respiratory muscle weakness, older age and long‐term immunosuppressive treatment.
M. Jakubíková, M. Týblová, Adam Tesař, Magda Horáková, Daniela Vlažná, Irena Ryšánková, I. Nováková, K. Doleckova, P. Dušek, J. Piťha, S. Voháňka, J. Bednařík   +11 more
semanticscholar   +1 more source

Meta-analysis of subxiphoid approach versus lateral approach for thoracoscopic Thymectomy

Journal of Cardiothoracic Surgery, 2020
Background Compared with traditional open surgery for thymectomy, video-assisted thoracoscopic surgery (VATS) reduces hospital stay, decreases postoperative pain, and recovers faster. VATS has become increasingly popular in the past decade.
Jiaduo Li, Guoyan Qi, Yaling Liu, Xuguang Zheng, Xiaohe Zhang   +4 more
doaj   +1 more source

Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis

Journal of Translational Medicine, 2021
Background Myasthenia gravis is a neuromuscular autoimmune disorder characterized by weakness and disability in the voluntary muscles. There have been several preliminary studies on the epidemiology of myasthenia gravis in different parts of the world ...
N. Salari, Behnaz Fatahi, Yalda Bartina, Mohsen Kazeminia, Reza Fatahian, P. Mohammadi, S. Shohaimi, M. Mohammadi   +7 more
semanticscholar   +1 more source

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis : a subgroup analysis of the REGAIN open-label extension study [PDF]

, 2019
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229).
De Bleecker, Jan, Fujita, KP, Imai, T, Murai, H, O'Brien, F, Okumura, M, Shiraishi, H, Study Group, REGAIN, Suzuki, H, Suzuki, Y, Utsugisawa, K, Uzawa, A, Wang, JJ   +12 more
core   +1 more source

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics

Frontiers in Immunology, 2020
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by autoantibodies targeting neuromuscular junction proteins.
K. Lazaridis, S. Tzartos
semanticscholar   +1 more source

A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations [PDF]

, 2019
Background: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission. Exacerbations may involve increasing bulbar weakness and/or sudden respiratory failure, both of which can be critically disabling.
Ayguasanosa, J, Balasa, R, Bril, V, Camprubi, S, Chen, J, De Bleecker, Jan, Garcia, B, Griffin, R, Heckmann, JM, Henriquez, W, Karelis, G, Lagrange, E, Mondou, E, Nicolle, M, Stuchevskaya, T, Van Damme, P, Vilciu, C, Villa, A   +17 more
core   +2 more sources